Cytosorbents (CTSO) Common Equity (2010 - 2026)

Cytosorbents (CTSO) has 17 years of Common Equity data on file, last reported at $2.2 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 84.91% year-over-year to $2.2 million; the trailing twelve-month figure through Mar 2026 stood at $2.2 million (down 84.91% YoY), and the FY2025 full-year result was $5.9 million, down 46.85% from the prior year.
• Common Equity for Q1 2026 stood at $2.2 million, down from $5.9 million in the prior quarter.
• Across five years, Common Equity topped out at $55.4 million in Q1 2022 and bottomed at $2.2 million in Q1 2026.
• The 5-year median for Common Equity is $18.8 million (2023), against an average of $22.3 million.
• The widest annual swing landed in 2025, when Common Equity fell 25.89%; it then tumbled 84.91% in 2026.
• A 5-year view of Common Equity shows it stood at $35.4 million in 2022, then sank by 33.63% to $23.5 million in 2023, then tumbled by 52.7% to $11.1 million in 2024, then tumbled by 46.85% to $5.9 million in 2025, then slumped by 62.83% to $2.2 million in 2026.
• The last three Common Equity figures came in at $2.2 million (Q1 2026), $5.9 million (Q4 2025), and $9.0 million (Q3 2025), per Business Quant data.

Peer Comparison